Clinical Trial: A Study of LAD106 in Healthy Adult Participants

U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07471932) titled 'A Study of LAD106 in Healthy Adult Participants' on March 06.

Brief Summary: The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.

Study Start Date: Feb. 17

Study Type: INTERVENTIONAL

Condition: Healthy Volunteers

Intervention: DRUG: LAD106

LAD106 will be administered.

DRUG: Lebrikizumab

Lebrikizumab will be administered.

OTHER: Placebo

Placebo matching LAD106 will be administered.

Recruitment Status: RECRUITING

Sponsor: A...